Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

Research output: Contribution to journalReview article

245 Scopus citations

Abstract

Therapeutic success in the superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS) has not translated into effective therapy for human ALS, calling into question the utility of such preclinical data for identifying therapeutic agents that are worthy of further study in humans. This random effects meta-analysis of treatment trials in the superoxide dismutase (SOD1) mouse was undertaken in order to explore possible reasons for this failure of translational research and to identify potential pharmacological interventions that might be used in either a preventative or therapeutic trial in familial ALS. Among studies in which treatment was initiated presymptomatically, the weighted mean differences (WMDs) comparing the active treatment to control treated animals were 12 days (onset), 13 days (survival) and 5 days (survival interval). Among studies in which treatment was initiated at the time of symptom onset, the WMDs were 15 days (survival) and 8 days (survival interval). Subgroup analysis suggests that drugs such as minocycline and Cox-2 inhibitors with an anti-inflammatory mechanism of action, and anti-oxidative agents such as creatine or the manganese porphyrin AEOL-10150, appear to be the most promising for preventative and therapeutic trials respectively in patients with familial ALS. These conclusions should be tempered by the methodological limitations of the relevant literature.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalNeurobiology of Disease
Volume26
Issue number1
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

    Fingerprint

Keywords

  • Amyotrophic lateral sclerosis
  • Animal model
  • Familial ALS
  • G93A
  • Meta-analysis
  • Motor neuron disease
  • Mouse model
  • SOD1 mouse
  • Systematic review
  • Treatment trials

ASJC Scopus subject areas

  • Neurology

Cite this